Meghmani Organics Limited · NSE:MOL
Meghmani Organics — Investor Presentation (February 2021)
43 slides from Meghmani Organics's investor presentation, February 2021
Slide 1: Meghmani Organics Limited Corporate Presentation
Meghmani Organics Limited (MOL) Corporate Presentation February 2021
Slide 2: Safe Harbour
Safe Harbour The presentation has been prepared by Meghmani Organics Limited (“MOL” or the “Company”) solely for information purposes and does not constitute an offer to sell or, recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall
Slide 3: From the Desk of the Chairman
From the Desk of the Chairman “We are committed to follow good and transparent business practices. These values shall be the base and the backbone for all our endeavors to achieve our ‘Corporate Vision’. The board of directors of the company and every single senior personnel of management is committ
Slide 4: The Corporate Vision
The Corporate Vision To become one of the leading diversified chemical companies in ‘Organic Chemistry’ aiming global presence with worldwide product acceptability. To setup world class development centre to facilitate upgrading technical capabilities and cost effective measures 4
Slide 5: Core Values
Core Values Integrity Credibility Being Human Law abiding Environment and Safety 5
Slide 6: The Management Commitments
The Management Commitments The board of directors including the senior management is committed to: stick to the core businesses in organic chemistry offering innumerable growth opportunities; build high standard manufacturing base, adhere to prescribed ‘Environmental & Safety Standards’ and st
Slide 7: Leading Diversified Chemicals Company Poised for Rapid Growth
Leading Diversified Chemicals Company Poised for Rapid Growth Pigments Agrochemicals Chloro Alkali & its Derivatives (MFL) • Started in 1986 • Started in 1995 • Started in 2009 • Amongst top 3 global Phthalocyanine • One of the largest producers of • 4th largest Chloro-Alkali & its based pigment pla
Slide 8: The Advantage MOL
The Advantage MOL Focused on manufacturing technical and intermediates to cater sustainable worldwide requirements round the year and optimize use the manufacturing capacities. The well integrated manufacturing base and plants located in chemical hub of Gujarat, Well-balanced plant capacities
Slide 9: Growth Drivers
Growth Drivers Macro and Micro growth drivers: MOL Revenue Drivers: Increasing population Composite Product Basket-Presence over entire value chain Decreasing Arable land Registration strength~ 656 CIB+Exports Domestic consumption @ 0.6 Kg/Acre in Wide geographical spread across all cont
Slide 10: SCOT - MOL
SCOT- MOL Strength: Opportunities: • Investment in Manufacturing Infrastructure. • Make in India initiative by the Govt. • Enough Manufacturing capacity to support growth plan. • Backward integration for higher value • Focus on Backward Integration addition and reduce dependence. • Geographically Di
Slide 11: Financial Policies, Capital Allocation and Dividend
Financial Policies , Capital Allocation and Dividend • Consistently improving Debt/Equity : From 0.76 in 2016 to 0.57 in FY20. We will maintain Debt Equity ~ 0.6 • Net Working Capital days ( Debtors+inventory-payables) : Consistently improving NWC days from 116 in FY 2016 to 100 days in FY20. Target
Slide 12: Growth Plan (Agro Division) – Achieve Top line of Rs. 2000 Cr by FY24
Growth Plan (Agro Division) – Achieve Top line of Rs. 2000 Cr by FY 24 Capex Expected date of Expected Revenue Project (Rs Crs) Completion (Rs Crs) 2,4-D (Capacity – 10.8k 127 Commissioned in Q3 FY 21 200 TPA) Phase-I: commissioned in Q3 FY 21 Formulation Plant 25 150 Phase II : Q1 FY 22 Multi Purpo
Slide 13: Growth Plan-Chloro-Alkali & its Derivatives (1/2)
Growth Plan-Chloro-Alkali & its Derivatives: Achieve Top line of Rs. 2000 Cr by FY 24 (1/2) Completed Projects Expected Revenue Project Capacity Date of Commissioning (Rs Crs) CMS 50 KTA July 19 160 Caustic Expansion 140 KTA June 20 300 CPP Exp 36 MW June 20 Hydrogen Peroxide 60 KTA July 20 150 Tota
Slide 14: Growth Plan-Chloro-Alkali & its Derivatives (2/2)
Growth Plan-Chloro-Alkali & its Derivatives: Achieve Top line of Rs. 2000 Cr by FY 24 (2/2) New Investments : Rs. 695 Cr Project Capacity Date of Commissioning Expected Revenue (Rs Crs) Epichlorohydrin (ECH) 50 KTA Q4 FY 22 475 CPVC Resin 30 KTA Q1 FY 23 300 Caustic Soda with Captive Power 106 KTA &
Slide 15: Chloro-Alkali & its Derivatives (Increasing Share of Value added products)
Chloro-Alkali & its Derivatives (Increasing Share of Value added products) 2019-2020 (A) Chloro-Alkali Segment KOH 20% Derivatives Chloro- (CMS) Alkali 83% 17% NaOH 80% The division’s share of value added products is expected to grow from 17% in FY20 to 57% in FY24 Chloro-Alkali Segment Year 2023-20
Slide 16: The Board of Directors
The Board of Directors Mr. Jayanti Patel Mr. Ashish Soparkar Mr. Natwarlal Patel Mr. Ramesh Patel Mr. Anand Patel Executive Chairman Managing Director Managing Director Executive Director Executive Director • 37 yrs of experience • 37 yrs of experience • 35 yrs of experience • 31 yrs of experience •
Slide 17: The Independent Directors
The Independent Directors Sri Manubhai K. Patel is a Chartered Accountants with more than 37 years of experience in the field of Forex, Treasury and Credit Management. He is on board of Meghmani Finechem Limited. Besides he holds directorship in GVFL Trustee Company Private Limited, Paryavaran Edute
Slide 18: The Independent Directors
The Independent Directors Mr. Bhaskar Rao is resident in Singapore. Mr. Rao holds Post Graduate Diploma in Management (Indian Institute of Management, Calcutta). Presently, Mr. Rao is an Independent consultant in the field of finance, legal and commercial partnerships. He has worked with some of the
Slide 19: The Second Generation
The Second Generation Mr. Ankit Patel Mr. Maulik Patel Mr. Kaushal Soparkar Mr. Darshan Patel Mr. Karana Patel CEO (MOL) CMD (MFL) MD (MFL) COO (Pigments) MOL COO (Agrochemicals) MOL • 10 yrs of experience • 12 yrs of experience • 11 yrs of experience • 7 yrs of experience • 11 yrs of experience • E
Slide 20: Q3 FY21 Results Update
• Exports to 75+ Countries Q3• FY21 Results Subsidiaries Dubai and in US, Update representative office in China • 7 Dedicated Manufacturing Facilities in India 20
Slide 21: Q3 & 9M FY21 Results: Key Highlights
Q3 & 9M FY21 Results: Key Highlights Q3 FY21 YoY Analysis Rs Mn Revenues & Gross Margin EBITDA & EBITDA Margin PAT & PAT Margin* 46.8% 48.3% 24.2% 20.0% 10.9% 12.1% 6,577 1,591 5,222 1,047 793 567 Q3 FY20 Q3 FY21 Q2 FY20 Q2 FY21 Q3 FY20 Q3 FY21 9M FY21 YoY Analysis 44.3% 49.5% 21.0% 25.0% 13.9% 12.8
Slide 22: Q3 FY21 Results: Key Highlights
Q3 FY21 Results: Key Highlights • During Q3 FY21, Meghmani’s operations returned to normalcy with capacity utilization returning to pre- COVID-19 levels. The company’s operations were carried out under restrictive manufacturing environment with utmost priority to the safety of plants and its employe
Slide 23: Q3 & 9M FY21 Results: Pigments Business
Q3 & 9M FY21 Results: Pigments Business Q3 FY21 YoY Analysis Rs Mn Production & Utilisation (%) Net Revenue (Rs Mn) & Exports* EBITDA (Rs Mn) & Margin (%) 89% 86% 81 % 77 % 9,000 600 16.8% 19.1% 8,000 7,323 7,099 50.0% 1,623 500 20.0% 0.0% 1,700 7,000 1,600 1,525 10.0% 6,000 -50.0% 400 310 5,000 -10
Slide 24: Q3 & 9M FY21 Results: Agrochemicals Business
Q3 & 9M FY21 Results: Agrochemicals Business Q3 FY21 YoY Analysis Rs Mn Production & Utilisation (%) Net Revenue (Rs Mn) & Exports* EBITDA (Rs Mn) & Margin (%) 82% 83 % 88 % 60% 10,000 1,200 20.7% 24.6% 30.0% 50.0% 8,000 6,641 3,000 2,825 1,000 20.0% 6,000 4,854 0.0% 800 696 10.0% 2,500 2,226 4,000
Slide 25: Q3 & 9M FY21 Results: Chloro Alkali & its Derivatives Business
Q3 & 9M FY21 Results: Chloro Alkali & its Derivatives Business Q3 FY21 YoY Analysis Rs Mn Production & Utilisation (%) Net Revenue (Rs Mn) EBITDA (Rs Mn) & Margin (%) 83% 89% 26.6% 30.9% 1,200 30.0% 100,000 83,169 50.0% 3,000 1,000 20.0% 80,000 2,215 0.0% 2,500 800 684 10.0% 60,000 49,521 2,000 1,56
Slide 26: Q3 FY21 Results: Consolidated Profit & Loss Statement
Q3 FY21 Results: Consolidated Profit & Loss Statement Particulars (Rs. in Mn) Q3 FY21 Q3 FY20 YoY% 9M FY21 9M FY20 YoY% Revenue from Operations 6,577 5,222 25.9% 17,113 16,708 2.4% COGS 3,403 2,777 22.6% 8,647 9,300 -7.0% Gross Profit 3,173 2,445 29.8% 8,466 7,409 14.3% Gross Margins % 48.3% 46.8% 1
Slide 27: Composite Scheme of Arrangement
• Exports to 75+ Countries Composite Scheme of • Subsidiaries in US, Arrangement Dubai and representative office in China • 7 Dedicated Manufacturing Facilities in India 27
Slide 28: Restructuring - Approvals & Indicative Timeline
Restructuring - Approvals & Indicative Timeline Sr. No. Key Approvals Indicative Timelines 1 Prior approval of Singapore stock exchange and Securities Industries council In principle approval obtained 2 Receipt of observations/comments from Stock exchanges on the scheme and Securities Approval recei
Slide 29: Scheme of Arrangement
Scheme of Arrangement MEGHMANI ORGANICS LTD (MOL) MEGHMANI FINECHEM LTD (MFL) Investment “Other Business” Agro in RPS* of Pigments (Trading + Equity Chlor Alkali & its Derivatives Chemicals MFL Investment in MFL) Demerger Amalgamation of “Other Business” of MOL with MFL Meghmani Organochem Ltd (WOS
Slide 30: Rationale for the Restructuring
Rationale for the Restructuring Aimed to position ‘Chloro Alkali and its Derivatives’ as independent and sustainable businesses The business dynamics and growth trajectories Objectives deserves a status of an independent company. Strengthen and further improve operational efficiencies of both
Slide 31: Rationale for the Restructuring: Value unlock
Rationale for the Restructuring Unlocking value of the ‘Chloro Alkali and its Derivatives’ business currently embedded in the value of MOL Separate and independent listing of MFL and MOL Shareholders of MFL to gain from business valuations of high Value unlock growth prone ‘Chloro Alkali and i
Slide 32: Rationale for the Restructuring: Delisting from Singapore Stock Exchange
Rationale for the Restructuring Shares (SDSs) issued by MOL under depository mechanism on SGX will be delisted Delisting from Singapore Stock Exchange Saving in high recurring cost of listing Additional compliances for 3rd exchange ( Only 5% equity shares now listed) Strong Potential to unlock
Slide 33: Share Capital Structure (MOL) Post Demerger
Share Capital Structure (MOL) Post Demerger There will not be any change in Shareholding pattern of MOL post demerger. MOL shareholder’s will get 94 shares(FV Rs10) of MFL for every 1000 shares held in MOL (FV Rs 1). MOL Shareholding- Pre and Post Demerger Particulars No of shares (FV Rs 1 ) % T
Slide 34: Share Capital Structure (MFL) Post Demerger
Share Capital Structure (MFL) Post Demerger MFL Shareholding Pre-Demerger New Shares to be issued by MFL as per Scheme Particulars No of Shares (FV10) %age Total No of shares in MOL 254,314,211 MOL 23,545,985 57.16% Swap Ratio 0.94 Individual New shares to be issued by MFL to 17,647,129 42.84% 23,90
Slide 35: Financial Performance at a Glance
• Exports to 75+ Countries Financial Performance at a • Subsidiaries in US, Dubai and Glance representative office in China • 7 Dedicated Manufacturing Facilities in India 35
Slide 36: Pigments Business: Operational Overview
Pigments Business: Operational Overview Production (MT) Net Revenue & Exports* (Rs Mn) 75 % 68 % 79 % 81 % 77 % 78 % 25,982 25,226 25,694 26,000 6,048 6,406 20,194 5,877 21,000 18,050 6,100 5,242 5,100 4,185 16,000 4,100 11,000 3,100 2,100 6,000 1,100 1,000 100 FY17 FY18 FY19 FY20 9m FY21 FY17 FY18
Slide 37: Agrochemicals Business: Operational Overview
Agrochemicals Business: Operational Overview Registrations Base Production (MT) 25,000 646 656 581 567 616 18,431 18,666 18,145 18,669 492 20,000 16,219 14,004 348 356 362 15,000 354 307 309 10,000 227 260 268 290 294 5,000 183 0 FY16 FY17 FY18 FY19 FY20 9M FY21 FY16 FY17 FY18 FY19 FY20 9M FY21 Expo
Slide 38: Chloro-Alkali & its Derivatives Business: Operational Overview
Chloro-Alkali & its Derivatives Business: Operational Overview Production (MT) & Capacity Utilisation (%) Net Sales (Rs Mn) 88.0% 77.0% 80.2% 8,000 7,104 350,000 86.0% 86.1% 84.2% 100.0% 90.0% 7,000 5,975 6,098 5,701 300,000 80.0% 6,000 250,000 205,480 70.0% 3,988 179,203 5,000 3,920 200,000 145,985
Slide 39: Standalone Financial Snapshot
Standalone Financial Snapshot Rs Mn Revenues ^ & Gross Margin EBITDA & EBITDA Margin PAT & PAT Margin * CAGR 14% * CAGR 21% * CAGR 52% 11.9% 12.9% 21.2% 12.0% 46.8% 39.7% 42.1% 42.5% 16.5% 36.2% 38.0% 14.5% 6.2% 1,921 13.6% 10.8% 11.9% 2,466 3.8% 4.0% 1,687 16,247 2,323 2,363 1,503 12,605 14,104 11,
Slide 40: Standalone Financial Snapshot
Standalone Financial Snapshot Rs Mn Leverage Analysis Working Capital Analysis * 0.68 0.56 0.60 142 130 0.39 0.27 0.25 112 115 113 106 96 82 81 65 77 74 6,977 11,395 5,916 8,380 9,908 6,329 101 103 89 85 92 92 4,037 3,533 4,170 3,265 2,639 2,874 -55 -55 -48 -50 -51 -60 FY16 FY17 FY18 FY19 FY20 9M FY
Slide 41: Consolidated Financial Snapshot
Consolidated Financial Snapshot Rs Mn Revenues ^ & Gross Margin EBITDA & EBITDA Margin PAT & PAT Margin * CAGR 13% * CAGR 14% * CAGR 27% 49.5% 50.5% 49.5% 46.9% 44.1% 26.1% 25.0% 13.2% 14.1% 13.2% 12.8% 43.5% 23.9% 19.6% 20.3% 19.8% 8.4% 8.2% 2,954 2,890 20,880 21,912 5,445 18,034 2,379 2,188 17,113
Slide 42: Consolidated Financial Snapshot
Consolidated Financial Snapshot Rs Mn Leverage Analysis Working Capital Analysis * 0.76 0.62 0.57 0.51 116 112 0.53 0.35 91 100 92 87 16,153 13,983 11,528 80 71 64 63 52 59 7,575 8,732 10,919 80 85 71 70 80 77 7,901 8,220 -36 5,781 4,610 3,858 7,162 -44 -44 -39 -44 -48 FY16 FY17 FY18 FY19 FY20 9M FY
Slide 43: For Further Queries
For Further Queries: Mr. Gurjant Singh Chahal, CFO Email: [email protected] Phone: +91-79717 61000 Mr. Bharat Mody Advisor – IR Mobile : +91 98980 46584 E mail : [email protected] Hiral Keniya / Vikash Verma IR Consultants Contact: 90296 62801 / 96640 09029 Email: [email protected]
Meghmani Organics — Investor Presentation (February 2021) on 6ix